Lipocine to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

Lipocine to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

Lipocine Inc., a biopharmaceutical company specializing in Central Nervous System (CNS) disorders, has announced that its President and CEO, Dr. Mahesh Patel, will be presenting and meeting with investors at the 2023 Cantor Fitzgerald Global Healthcare Conference. The conference will take place from September 26th to September 28th in New York City.

The format of the presentation will be a Panel Presentation, in conjunction with Fennec Pharmaceuticals Inc. The presentation is scheduled for Wednesday, September 27th, from 3:00-3:30 PM ET. Lipocine will be presenting at Track 4 of the conference, which will be held at the InterContinental NY Barclay Hotel.

For those interested in scheduling a one-on-one meeting with Lipocine management, they can do so by contacting their representative at Cantor Fitzgerald.

Lipocine is a biopharmaceutical company that focuses on developing differentiated products for CNS disorders through effective oral delivery. Their drug candidates utilize their proprietary technology platform and aim to address significant unmet medical needs in large markets. Currently, Lipocine has several clinical development candidates, including LPCN 1154 for postpartum depression, LPCN 2101 for epilepsy, and LPCN 1148 for symptoms associated with liver cirrhosis.

In addition to their ongoing drug development efforts, Lipocine also explores partnering opportunities for potential treatments of preterm birth, non-cirrhotic NASH, and testosterone replacement therapy.

Lipocine’s FDA-approved product, TLANDO, is an oral prodrug of testosterone that is used to treat conditions associated with a deficiency of endogenous testosterone in adult males.

Forward-looking statements made by Lipocine in this announcement caution investors that there are risks and uncertainties inherent in the development and commercialization process of their product candidates. These risks include potential development failures, a lack of sufficient capital, regulatory approval challenges, and unexpected clinical trial results.

More information about Lipocine and their product candidates can be found on their website at

Source: Lipocine Inc.

All Rights Reserved 2021.
| .